The allegations centre on an unusually rapid increase in Ranbaxy’s share price in the week before the deal was announced. Sun Pharma has denied any wrongdoing, saying in a statement that: ‘The matter related to purchase of shares of Ranbaxy Laboratories does not violate insider trading rules.’